免疫檢查點抑制劑市場、機會、成長動力、產業趨勢分析與預測，2024-2032

Immune Checkpoint Inhibitors Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月20日 | 出版商:

Global Market Insights Inc. | 英文 120 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023 年，全球免疫檢查點抑制劑市場達到474 億美元，預計2024 年至2032 年複合年成長率為16.7%。。免疫檢查點抑制劑增強免疫系統針對癌細胞的能力，對黑色素瘤、肺癌和腎細胞癌有效。廣泛的臨床試驗、有利的監管批准以及與治療方案的整合支持了市場擴張。對腫瘤學研究的投資增加和新抑制劑的強大管道維持了市場成長。例如，2021年7月，蘭金政府投資1,800萬美元用於癌症治療，包括免疫檢查點抑制劑。 2023年，癌症研究所撥款2,800萬美元用於癌症免疫治療研究。政府和組織實體的這種支持對於市場成長至關重要。

整個免疫檢查點抑制劑行業根據類型、應用、最終用途和地區進行分類。

免疫檢查點抑制劑阻斷稱為檢查點的蛋白質，增強免疫細胞攻擊癌細胞的能力。市場按類型分類：PD-L1、CTLA-4、PD-1 等。 PD-1 細分市場在 2023 年佔據主導地位，銷售額為 347 億美元。 PD-1 抑制劑，如納武單抗和派姆單抗，在多種癌症中顯示出令人印象深刻的療效，包括非小細胞肺癌、黑色素瘤和腎細胞癌。穩健的臨床結果和腫瘤學實踐中不斷成長的採用鞏固了 PD-1 抑制劑的領先市場地位。

市場按應用細分為黑色素瘤、乳癌、肺癌、膀胱癌、何杰金氏淋巴瘤、子宮頸癌、大腸直腸癌等。 2023 年，肺癌佔首位，佔 25.1%。肺癌的巨大負擔和這些療法已被證實的療效可提高患者的治療效果。 2023年，美國新診斷出238,340例肺癌，約127,070人死亡。針對 PD-1、PD-L1 和 CTLA-4 的免疫檢查點抑制劑已在治療非小細胞肺癌 (NSCLC) 方面取得了成功。正在進行的研究和臨床試驗正在擴大這些抑制劑在不同肺癌階段的應用。

2023年，北美市場佔有率為229億美元，預計2024年至2032年複合年成長率為16.8%。美國癌症協會估計，2024 年美國和加拿大將新增約 2,170,450 例癌症病例，凸顯了對先進癌症療法的需求。此外，政府對癌症研究和治療的資助增加進一步推動了該地區市場的成長。

產業生態系統分析
產業影響力
- 成長動力
  - 全球癌症發生率不斷上升
  - 免疫療法的持續研究和開發
  - 有利的監管環境
  - 增加投資和夥伴關係
- 產業陷阱與挑戰
  - 治療費用高
  - 不良副作用
成長潛力分析
監管環境
管道分析
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按類型，2021 - 2032

主要趨勢
PD-1
PD-L1
CTLA-4
其他類型

第 6 章：市場估計與預測：按應用分類，2021 - 2032

主要趨勢
肺癌
乳癌
膀胱癌
黑色素瘤
子宮頸癌
霍奇金淋巴瘤
大腸直腸癌
其他應用

第 7 章：市場估計與預測：按最終用途，2021 - 2032 年

主要趨勢
醫院和診所
癌症中心
學術及研究機構

第 8 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 沙烏地阿拉伯
- 南非
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 9 章：公司簡介

AstraZeneca PLC
BeiGene, Ltd.
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline plc
Incyte Corporation
Immutep Limited
Merck and Co., Inc.
Regeneron Pharmaceuticals, Inc.
Sanofi
Shanghai Junshi Biosciences Co., Ltd.

簡介目錄

Product Code: 10860

The Global Immune Checkpoint Inhibitors Market reached USD 47.4 billion in 2023 and is projected to register a CAGR of 16.7% from 2024 to 2032. This growth is driven by the rising global cancer prevalence and demand for advanced, personalized therapies. Immune checkpoint inhibitors enhance the immune system's ability to target cancer cells, showing effectiveness against melanoma, lung cancer, and renal cell carcinoma. Extensive clinical trials, favorable regulatory approvals, and integration into treatment protocols support market expansion. Increased investments in oncology research and a strong pipeline of new inhibitors sustain market growth. For instance, in July 2021, the Rankin government invested USD 18 million in cancer therapies, including immune checkpoint inhibitors. In 2023, the Cancer Research Institute allocated USD 28 million for cancer immunotherapy research. Such support from governmental and organizational entities is crucial for market growth.

The overall immune checkpoint inhibitors industry is classified based on the type, application, end-use, and region.

Immune checkpoint inhibitors block proteins known as checkpoints, enhancing immune cells' ability to attack cancer cells. The market is categorized by type: PD-L1, CTLA-4, PD-1, and others. The PD-1 segment dominated in 2023 with USD 34.7 billion. PD-1 inhibitors, like nivolumab and pembrolizumab, show impressive efficacy across various cancers, including non-small cell lung cancer, melanoma, and renal cell carcinoma. Robust clinical outcomes and growing adoption within oncology practices reinforce the leading market position of PD-1 inhibitors.

The market is segmented by application into melanoma, breast cancer, lung cancer, bladder cancer, Hodgkin lymphoma, cervical cancer, colorectal cancer, and others. In 2023, lung cancer led with a 25.1% share. Lung cancer's significant burden and the proven efficacy of these therapies enhance patient outcomes. In 2023, the U.S. saw 238,340 new lung cancer diagnoses, with approximately 127,070 fatalities. Immune checkpoint inhibitors targeting PD-1, PD-L1, and CTLA-4 have shown success in treating non-small cell lung cancer (NSCLC). Ongoing research and clinical trials are broadening the application of these inhibitors across various lung cancer stages.

In 2023, North America held a USD 22.9 billion share of the market, with a projected CAGR of 16.8% from 2024 to 2032. The presence of leading pharmaceutical companies and a favorable regulatory landscape bolster the North American market. The American Cancer Society estimates around 2,170,450 new cancer cases in the U.S. and Canada in 2024, highlighting the demand for advanced cancer therapies. Additionally, increasing government funding for cancer research and treatment is further driving the market's growth in the region.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising cancer incidence across the world
  - 3.2.1.2 Ongoing research and development in immunotherapy
  - 3.2.1.3 Favorable regulatory environment
  - 3.2.1.4 Increasing investments and partnerships
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of treatment
  - 3.2.2.2 Adverse side effects
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 PD-1
5.3 PD-L1
5.4 CTLA-4
5.5 Other types

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Lung cancer
6.3 Breast cancer
6.4 Bladder cancer
6.5 Melanoma
6.6 Cervical cancer
6.7 Hodgkin lymphoma
6.8 Colorectal cancer
6.9 Other applications

Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospitals and clinics
7.3 Cancer centers
7.4 Academic and research institutes

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 Saudi Arabia
- 8.6.2 South Africa
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa